20 kinds of magic drugs stepped down from the altar and involved 10bn markets

From Abuse to Regular Use" caused industry shock, and the standardized use of auxiliary drugs became the focus of society. After several months, the first batch of national key drug surveillance catalogues were released to the outside world.

On July 1, the official website of the State Health and Health Commission issued the Notice on the Issuance of the First National Catalogue of Key Controlled and Rational Drugs for Drugs Use (Chemicals and Biological Products). Ganglioside, Encephalin, Carnosine, Olasitan, Calf Serum Deproteinization, Salvia Miltiorrhiza, Ligustrazine and Cinepazide maleate were 20 kinds of drugs. It has been listed in the list of national key monitoring catalogues. It is known that most of these drugs are large varieties of clinical applications. According to the statistics of "Securities Daily", four of the 20 kinds of drugs are the exclusive varieties of enterprises. For example, Beijing Double Heron Pharmaceutical Co., Ltd. (24.190, -0.07, -0.29%) is the manufacturer of compound coenzyme for injection. Will the event of have an impact on the product sales of listed companies? "Securities Daily" reporter contacted by telephone Shuanglu Pharmaceutical Director's Secretariat Office, the company's people said that the company is also assessing, the specific impact depends on the implementation of the policy. Doctors prescribe drugs based on clinical data.

The use of auxiliary medicines has been the focus of social attention. Under the influence of policies such as medical insurance and control fees, the Water of auxiliary medicines is gradually squeezed out. Xinjiang and other provinces had published the surveillance catalogue of adjuvant drugs. In December 2018, the State Health and Health Commission issued the Notice on the Management of Clinical Application of Auxiliary Drugs, and the national version of the catalogue of Auxiliary Drugs is about to come out.

On July 1, the announcement on the publication of the first batch of national key monitoring and control catalogues of rational drug use (chemical drugs and biological products) on the official website of the State Health and Health Commission marked the upgrading of monitoring and control of auxiliary drugs at the national level. In the above notification, the State Health and Health Commission requested that medical institutions should establish a management system for monitoring and controlling rational drug use, and strengthen the whole process management of drug clinical application in the catalogue. We should further standardize physicians'prescription behavior, formulate medication guidelines or technical specifications for drugs included in the catalogue, and clearly stipulate the conditions and principles for clinical application. Where relevant medication guidelines or guidelines exist, they should be strictly implemented in accordance with the guidelines or principles. To review and comment on prescriptions of all drugs included in the catalogue, and to enhance publicity, feedback and utilization of the results of prescription comment. For those varieties with outstanding unreasonable drug use problems, measures such as ranking bulletin, rectification within a time limit, and elimination of the drug supply catalogue of our institute should be taken to ensure rational drug use. It is worth mentioning that for chemical and biological products not included in the catalogue, the above-mentioned Notice requires physicians to strictly implement the relevant provisions of the Prescription Management Measures, and reasonably select drug varieties and prescriptions in accordance with the indications prescribed in the drug instructions, the guidelines for disease diagnosis and treatment and the corresponding prescription authority. The route and dosage of administration, and prescription.

National Health and Health Commission requires that health administrative departments at all levels, competent departments of traditional Chinese medicine and medical institutions should establish and improve the monitoring and supernormal early warning system for clinical use of drugs. Emphasis will be laid on the clinical use of drugs included in the catalogue as the evaluation content of medical institutions and their principal leaders, combined with the verification, evaluation and performance evaluation of medical institutions, and timely publicity of the evaluation results. For drugs not yet included in the catalogue management, routine monitoring of clinical use should be done well, and problems such as abnormal increase in usage, no indication and overdose use should be found. Early warning should be strengthened and reasons should be found out. Those who violate the law and regulations should be dealt with seriously.